Sillajen explains Pexa-Vec trial failure – it was the rescue meds

South Korean biotech Sillajen was hit hard last week when its oncolytic virus therapy Pexa-Vec failed a phase 3 trial, but the company reckons it doesn’t spell the end of the program.